Form 4: Oncolytics Biotech Director Granted Stock Options

Oncolytics Biotech Inc. reports the grant of stock options to Director Angela Holtham, with vesting over three years.

Summary

• Angela Holtham, a Director at Oncolytics Biotech Inc., was granted 30,000 stock options on June 1, 2026.
• The exercise price for these options is $1.06, equivalent to the closing stock price on the grant date.
• The options vest in three equal annual installments, starting on June 1, 2027, contingent upon continued service.
• The total number of securities beneficially owned by Holtham after this transaction is 30,000 shares, held directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial or strategic development for the company.

Positives

• Director Angela Holtham received a stock option grant, aligning her interests with shareholders.
• The grant is structured with a three-year vesting schedule, incentivizing long-term commitment.
• The exercise price is set at the market price on the grant date, a standard practice for incentive options.

Risks

• The value of the stock options is directly tied to the future performance of Oncolytics Biotech Inc.'s stock price.
• Vesting is contingent on continued service, meaning the options could be forfeited if employment or service ceases before vesting dates.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The future outlook for the stock options depends on the company's stock performance and the reporting person's continued service.

Industry Context

StockSavvy.ai notes that the grant of stock options to directors is a common practice in the biotechnology sector to attract and retain key talent and align executive interests with shareholder value. The specific terms, including the exercise price and vesting schedule, are typical for such grants.

Stakeholder Impact

• Shareholders: The grant aligns director incentives with shareholder interests, potentially leading to decisions that enhance stock value. Dilution is minimal given the number of options granted.
• Employees: This filing does not directly impact employees, but successful company performance, incentivized by such grants, can benefit all staff.
• Management: Reinforces standard compensation practices for directors.

Next Steps

• Angela Holtham may exercise the vested stock options at her discretion until the expiration date.
• The company's stock performance will determine the ultimate value realized from these options.

Key Dates

Keywords

stock options, insider trading, Oncolytics Biotech, director compensation, equity grant, vesting schedule, SEC Form 4